Press releases
March 25, 2010 | medio: Press Release
Disitertide (P144), jointly developed by ISDIN and Digna Biotech showed a statistically significant improvement versus placebo in the patients that perceived improvement of the treated skin area affected by systemic sclerosis
More information
January 19, 2010
Digna Biotech starts the clinical research phase with interferon alpha-5 in patients with genotype 1 chronic hepatitis C that have not healed with previous treatment
More information
© Digna Biotech · Legal information · Company associated to ASEBIO 